Semax and Selank inhibit enkephalin-degrading enzymes from human serum
N V Kost, O Iu Sokolov, M V Gabaeva, I A Grivennikov, L A Andreeva, N F Miasoedov, A A Zozulia · 2001 · Bioorg Khim. 27(3):180–183
What does this source report?
Both peptides and certain fragments inhibited peptide-degrading enzymes in laboratory assays.
- Population and setting
- Human-serum enzyme assays
- Evidence type
- In vitro
- Preparation
- Original Semax / Selank research preparations; no equivalence to modified commercial analogues asserted
- Source language
- See original publication; indexed English metadata
- Title provenance
- Title as recorded in the linked source or index. A separate original-language title has not been transcribed unless shown above.
What are the limitations?
- Human-derived serum does not make this a patient trial.
- Assay concentrations and enzyme effects do not establish a clinical mechanism or benefit.
Publication counts are not counts of independent trials. Reviews, translations and reports sharing participants may overlap. Findings apply to the studied preparation, population and endpoints.
Source access and review scope
Indexed citation and English abstract checked; full methods and risk of bias not appraised.
Recorded source-check date: 2026-09-30. This date does not imply a completed systematic review.
Source provenance: Journal publication
Cite and trace this record
Original source: N V Kost, O Iu Sokolov, M V Gabaeva, I A Grivennikov, L A Andreeva, N F Miasoedov, A A Zozulia. Semax and Selank inhibit enkephalin-degrading enzymes from human serum Bioorg Khim. 27(3):180–183 2001.
Molekul research summary: https://molekul.io/research/ss-11443939. Cite the original publication for its findings and this page when referring to Molekul’s summary or evidence appraisal.
Bibliography entryRelated compound profiles
Semax
ACTH-fragment-derived peptide with clinical stroke and optic-nerve reports, healthy-volunteer imaging and preclinical neuroregulation research. Precursor, patent and dissertation sources remain separately labeled.
Selank
Tuftsin-derived peptide investigated in anxiety comparisons, stress models and neurochemical assays. Its clinical and laboratory evidence are kept distinct from unverified archival claims.